SAFETY AND EFFICACY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, UP TO 36 MONTHS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: DATA FROM THE THIRD INTERIM ANALYSIS OF OPAL BALANCE, AN OPEN-LABEL, LONG-TERM EXTENSION STUDY

被引：0
|
作者：
Nash, P. [1 ]
Coates, L. C. [2 ]
Kivitz, A. J. [3 ]
Mease, P. J. [4 ,5 ]
Gladman, D. D. [6 ]
Covarrubias-Cobos, J. A. [7 ]
Fleishaker, D. [8 ]
Wang, C. [8 ]
Kudlacz, E. [8 ]
Menon, S. [8 ]
Fallon, L. [9 ]
Hendrikx, T. [10 ]
Kanik, K. S. [8 ]
机构：
[1] Univ Queensland, Brisbane, Qld, Australia
[2] Univ Leeds, Leeds, W Yorkshire, England
[3] Altoona Ctr Clin Res, Duncansville, PA USA
[4] Swedish Med Ctr, Seattle, WA USA
[5] Univ Washington, Seattle, WA 98195 USA
[6] Univ Toronto, Toronto, ON, Canada
[7] Unidad Reumatol Las Americas SCP, Merida, Mexico
[8] Pfizer Inc, Groton, CT 06340 USA
[9] Pfizer Canada, Montreal, PQ, Canada
[10] Pfizer Inc, Collegeville, PA USA
来源：
INTERNAL MEDICINE JOURNAL | 2018年 / 48卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P11
引用
收藏
页码：15 / 15
页数：1
相关论文
共 50 条
  • [41] Long-term efficacy and safety with zonisamide: Interim analysis of an open-label study
    Wroe, S
    Brodie, MJ
    [J]. EPILEPSIA, 2005, 46 : 118 - 118
  • [42] Long-term Safety of Filgotinib in Patients with Psoriatic Arthritis, Week 52 Safety Data from a Phase 2 Open-Label Extension Study
    Coates, Laura
    Mease, Philip
    Gladman, Dafna
    Van den Bosch, Filip
    Rychlewska-Hanczewska, Anna
    Tasset, Chantal
    Meuleners, Luc
    Trivedi, Mona
    Gao, Jingjing
    Besuyen, Robin
    Helliwell, Philip
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [43] Long-Term Safety of Filgotinib in Patients with Psoriatic Arthritis, Week 52 Safety Data from a Phase 2 Open-Label Extension Study
    Gladman, Dafna
    Coates, Laura
    Mease, Philip
    van den Bosch, Filip
    Rychlewska-Hanczewska, Anna
    Tasset, Chantal
    Meuleners, Luc
    Trivedi, Mona
    Guo, Ying
    Besuyen, Robin
    Helliwell, Philip
    [J]. JOURNAL OF RHEUMATOLOGY, 2020, 47 (07) : 1066 - 1067
  • [44] ABP 501 Long-Term Safety/Efficacy: Interim Results from an Open-Label Extension Study
    Cohen, Stanley
    Pablos, Jose L.
    Zhang, Nan
    Rizzo, Warren
    Muller, Gerhard
    Padmanaban, Devi
    Kivitz, Alan
    Matsumoto, Alan K.
    Kaur, Primal
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [45] LONG-TERM EFFICACY OF THE ORAL SELECTIVE JANUS KINASE 1 INHIBITOR FILGOTINIB IN PSORIATIC ARTHRITIS: WEEK 52 RESPONSE PATTERNS IN INDIVIDUAL PATIENTS FROM AN OPEN-LABEL EXTENSION (OLE) STUDY (EQUATOR2)
    Gladman, D. D.
    Coates, L. C.
    Van den Bosch, F.
    Helliwell, P.
    Tasset, C.
    Meuleners, L.
    Gilles, L.
    Gheyle, L.
    Trivedi, M.
    Alani, M.
    Besuyen, R.
    Mease, P. J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 759 - 759
  • [46] TOFACITINIB, AN ORAL JAK INHIBITOR, IN THE TREATMENT OF ULCERATIVE COLITIS: OPEN-LABEL, LONG-TERM EXTENSION STUDY
    Bloom, Stuart
    Lichtenstein, Gary R.
    Loftus, Edward V.
    Lawendy, Nervin
    Friedman, Gary S.
    Zhang, Haiying
    Wang, Wenjin
    Thorpe, Andrew J.
    Nduaka, Chudy I.
    Su, Chinyu
    [J]. GUT, 2018, 67 : A62 - A63
  • [47] TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR: LONG-TERM EXTENSION STUDY OUTCOMES IN AN AUSTRALIAN RHEUMATOID ARTHRITIS POPULATION
    Hall, S.
    Nash, P.
    Rischmueller, M.
    Bossingham, D.
    Cook, N.
    Witcombe, D.
    Kwok, K.
    Thirunavukkarasu, K.
    [J]. INTERNAL MEDICINE JOURNAL, 2014, 44 : 26 - 26
  • [48] Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
    Jürgen Wollenhaupt
    Eun-Bong Lee
    Jeffrey R. Curtis
    Joel Silverfield
    Ketti Terry
    Koshika Soma
    Chris Mojcik
    Ryan DeMasi
    Sander Strengholt
    Kenneth Kwok
    Irina Lazariciu
    Lisy Wang
    Stanley Cohen
    [J]. Arthritis Research & Therapy, 21
  • [49] Long-Term Safety and Efficacy of Olokizumab in Patients with Rheumatoid Arthritis - Results of an Open-Label Extension Study
    Feist, Eugen
    Nasonov, Evgeny
    Luggen, Michael
    Fatenejad, Saeed
    Grishin, Sergey
    Samsonov, Mikhail
    Fleischmann, Roy
    [J]. ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 603 - 606
  • [50] TOFACITINIB, AN ORAL JAK INHIBITOR, IN THE TREATMENT OF RHEUMATOID ARTHRITIS: SAFETY AND CLINICAL AND RADIOGRAPHIC EFFICACY IN OPEN-LABEL, LONG-TERM EXTENSION STUDIES OVER 7 YEARS
    Wollenhaupt, J.
    Silverfield, J.
    Lee, E. B.
    Terry, K. K.
    Kwok, K.
    Lazariciu, I.
    Nduaka, C.
    Connell, C. A.
    DeMasi, R.
    Wang, L.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 252 - 252
12345